A multicenter Phase Ib/II trial reported clinically meaningful responses combining fruquintinib, a VEGFR inhibitor, with sintilimab, an anti‑PD‑1 antibody, in patients with mismatch-repair–proficient (pMMR) advanced endometrial cancer. The single-arm study demonstrated tumor control in a hard-to-treat population historically less responsive to immune checkpoint blockade. Investigators highlighted manageable toxicity and argued the regimen merits further randomized evaluation. If validated in larger studies, the combination could fill an unmet need for pMMR endometrial cancer and prompt comparative trials against current standards.